Expert Evaluation of Preclinical Toxicokinetic Studies of Pharmaceuticals (Review)
Tóm tắt
Literature data and domestic and foreign methodological documentation for preclinical studies of the safety and toxicokinetics of pharmaceuticals are analyzed. According to Marketing Authorization and Assessment Rules for Medicinal Products in the EAEU, a developer must include in a General Technical Document information on toxicokinetic studies that is evaluated during a review of preclinical test results. The main approaches to expert evaluation of drug toxicokinetic studies are formulated. The main content of the expert analysis includes the methodological basis and results of the research, safety profile characteristics, extrapolation of preclinical data, risk factor characteristics, and predicted clinical patient safety profile. The inclusion of toxicokinetic studies in a program of preclinical toxicological studies is important in principle for an adequate extrapolation of experimental data and prediction of the safety of pharmaceuticals in humans. Expert analysis of toxicokinetic data allows toxicology study results, drug toxicity profile characteristics, and the risk of toxic side effects to be interpreted correctly.
Tài liệu tham khảo
Decision No. 78 of the Eurasian Economic Commission Committee dated Nov. 3, 2016, “On the rules of registration and examination of medical drugs”; https: // goo.gl / s9NsVS.
Decision No. 78 of the Eurasian Economic Commission Committee dated Nov. 3, 2016, “On the rules of registration and examination of medical drugs,” Appendix 6, Rules of registration and examination of medicinal drugs, Appendix 6; https: //goo.gls9NsVS.
A. N. Mironov (ed.), Handbook for Preclinical Drug Trials [in Russian], Part 1, Grif i K, Moscow (2012).
A. N. Mironov (ed.), Handbook for Drug Review [in Russian], Vol. I, Grif i K, Moscow (2013).
Directive 2001 / 83 / EC of the European Parliament and of the Council of Nov. 6, 2001, On the Community Code Relating to Medicinal Products for Human Use.
ICH S3A Harmonised Tripartite Guideline Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies (1994).
P. G. Welling, Toxicol. Pathol., 23, 143 – 147 (1995).
L. Z. Benet and B. A. Hoener, Clin. Pharmacol. Ther., 71, 115 – 121 (2002).
M. Rowland and T. N. Tozer, Clinical Pharmacokinetics: Concepts and Applications, Lea & Febiger, Philadelphia (1980).
J. Tibbitts, Toxicol. Pathol., 31 (suppl), 17 – 24 (2003).
M. Rowland and T. N. Tozer, Clinical Pharmacokinetics: Concepts and Applications, 3rd Ed.,Williams &Wilkins, New York (1995).
P. D. Worboys and D. J. Carlile, Xenobiotica, 31(8 – 9), 539 – 556 (2001).
J. H. Lin and A. Y. H. Lu, Pharmacol. Rev., 49, 404 – 449 (1997).
A. Ghosal, N. Sadrieh, L. Reik, et al., Arch. Biochem. Biophys., 332(1), 153 – 162 (1996).
J. P. Jan Ploemen., H. Kramer, E. I. Krajnc, and I. Martin, Toxicol. Pathol., 35, 834 – 837 (2007).
D. B. Troy (ed.), Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins, Philadelphia (2005).
P. R. Mayer, Toxicol. Pathol., 23, 165 – 169 (1995).
D. K. Walker, S. Abel, P. Comby, et al., Drug Metab. Dispos., 33, 587 – 595 (2005).
RF Ministry of Health Order No. 558n dated Aug. 24, 2017, Consultant Plus Legal Reference System: Access Procedure: Local; http: // www.consultant.ru / document /cons doc LAW 285813 /
B. K. Romanov, R. N. Alyautdin, S. V. Glagolev, and V. A. Polivanov, Bezop. Risk Farmakoter., 2, 11 – 27 (2016).